DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Nebivolol in the Supine Hypertension of Autonomic Failure

Information source: Vanderbilt University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension; Pure Autonomic Failure; Multiple System Atrophy

Intervention: Placebo (Drug); Nebivolol 5 mg (Drug); metoprolol tartrate 50 mg (Drug); Sildenafil25 mg (Drug)

Phase: N/A

Status: Completed

Sponsored by: Vanderbilt University

Official(s) and/or principal investigator(s):
Italo Biaggioni, MD, Principal Investigator, Affiliation: Vanderbilt University

Summary

The purpose of this study is to evaluate the effect of the antihypertensive drug, nebivolol (Bystolic), compared to metoprolol (Lopressor) and sildenafil (Viagra) on blood pressure in patients with autonomic failure and supine hypertension.

Clinical Details

Official title: Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)

Primary outcome: Change in Systolic Blood Pressure During the Night

Secondary outcome:

Nocturnal Urinary Sodium Excretion

Orthostatic Tolerance the Following Morning

Change in Heart Rate During the Night

Detailed description: Nebivolol is distinct among beta-blockers by its ability to increase nitric oxide (NO) bioactivity. The contribution of this effect to the pharmacological actions of the drug, however, is difficult to ascertain in normal subjects because of the confounding contribution of the autonomic nervous system. Autonomic failure patients provide a unique model of hypertension devoid of autonomic modulation but sensitive to NO mechanisms. We propose to determine the effect of nebivolol on blood pressure in this patient population. A decrease in blood pressure will imply increased bioactivity of NO. Comparisons will be made with placebo, metoprolol (as a negative control) and sildenafil (as a positive control).

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female and aged 18 years or over.

- Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic

Failure (Parkinson Disease, Multiple System Atrophy and Pure Autonomic Failure).

- A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic

blood pressure of at least 10 mmHg, within 3 minutes after standing.

- Supine hypertension, defined as a systolic blood pressure >150 mm Hg or diastolic

blood pressure > 90 mm Hg.

- Provide written informed consent to participate in the study and understand that they

may withdraw their consent at any time without prejudice to their future medical care. Exclusion Criteria:

- Have changed dose, frequency and or type of prescribed medication, within two weeks

of study start.

- Women of childbearing potential who are not using a medically accepted contraception.

- Have, in the investigator's opinion, any significant cardiac, systemic, hepatic, or

renal illness.

- Diabetes mellitus or insipidus.

- In the investigator's opinion, have clinically significant abnormalities on clinical

examination or laboratory testing.

- In the investigator's opinion, are unable to adequately co-operate because of

individual or family situation.

- In the investigator's opinion, are suffering from a mental disorder that interferes

with the diagnosis and/or with the conduct of the study, e. g. schizophrenia, major depression, dementia.

- Are not able or willing to comply with the study requirements for the duration of the

study.

- Persons on drugs with beta-blocking potential (e. g., amiodarone), persons taking

scheduled or as needed nitrates and persons on drugs with alpha-blocking potential (e. g. tamsulosin).

Locations and Contacts

Vanderbilt University, Nashville, Tennessee 37232, United States
Additional Information

Autonomic Dysfunction Center. Vanderbilt University

Related publications:

Biaggioni I, Garcia F, Inagami T, Haile V. Hyporeninemic normoaldosteronism in severe autonomic failure. J Clin Endocrinol Metab. 1993 Mar;76(3):580-6.

Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995 Sep;274(3):1067-71.

Gamboa A, Shibao C, Diedrich A, Paranjape SY, Farley G, Christman B, Raj SR, Robertson D, Biaggioni I. Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure. Hypertension. 2008 Jun;51(6):1531-6. doi: 10.1161/HYPERTENSIONAHA.107.105171. Epub 2008 Apr 21.

Gupta S, Wright HM. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther. 2008 Fall;26(3):189-202. doi: 10.1111/j.1755-5922.2008.00054.x. Review.

Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic failure and its treatment. Hypertension. 1997 Nov;30(5):1062-7.

Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001 Jul 31;104(5):511-4.

Starting date: January 2010
Last updated: April 14, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017